文献速递皮肤肿瘤

薄层皮肤黑色素瘤患者死于黑色素瘤及其他原因的风险

Risk of Death Due to Melanoma and Other Causes in Patients With Thin Cutaneous Melanomas.
PubMed 文献 · JAMA Dermatol · 2025-01-01

结果显示,0.8至1.0 mm肿瘤的黑色素瘤相关死亡绝对风险显著高于<0.8 mm者,而非黑色素瘤相关死亡风险在各厚度间相似。

要点

  • 厚度0.8-1.0 mm的薄层黑色素瘤患者20年黑色素瘤相关死亡粗发生率为12.0%,高于<0.8 mm者的6.0%。
  • 多变量分析中,0.8-1.0 mm肿瘤的黑色素瘤相关死亡风险显著增加(亚分布风险比2.92,95%CI 2.74-3.12)。
  • 非黑色素瘤相关死亡风险与Breslow厚度无关,提示厚度主要影响黑色素瘤特异性死亡。

核心结论

  • 原发性肿瘤厚度0.8至1.0 mm的患者黑色素瘤相关死亡风险显著增加。
  • 非黑色素瘤相关死亡风险在Breslow厚度0.1至1.0 mm间相似。
  • 分析提示0.8 mm阈值可用于指导薄层原发性黑色素瘤患者的照护。

研究设计与样本

  • 基于澳大利亚全部8个州和领地人群癌症登记处的登记数据进行分析。
  • 纳入1982至2014年诊断为第一原发性浸润性黑色素瘤且厚度≤1.0 mm的成人。
  • 中位随访15.0年(IQR 9.5-23.3)。
  • 采用竞争风险回归分析和病因特异性分析评估Breslow厚度亚组(<0.8 mm vs ≥0.8 mm,按0.1 mm增量)与结局的关系。

主要发现

  • 全队列诊断后20年黑色素瘤相关死亡粗发生率为6.3%(95%CI 6.1%-6.5%)。
  • 肿瘤<0.8 mm者20年黑色素瘤相关死亡粗发生率为6.0%(95%CI 5.7%-6.2%),0.8至1.0 mm者为12.0%(95%CI 11.4%-12.6%)。
  • 对应20年黑色素瘤特异性生存率分别为91.9%(95%CI 91.6%-92.1%)、94.2%(95%CI 94.0%-94.4%)和87.8%(95%CI 87.3%-88.3%)。
  • 多变量分析中,0.8至1.0 mm肿瘤与更高的黑色素瘤相关死亡绝对风险相关(亚分布风险比2.92;95%CI 2.74-3.12)。
  • 0.8至1.0 mm肿瘤与更高的黑色素瘤相关死亡率相关(风险比2.98;95%CI 2.79-3.18)。

临床怎么用

  • 对于厚度0.8至1.0 mm的薄层原发性黑色素瘤患者,应认识到其黑色素瘤相关死亡风险显著高于<0.8 mm者。
  • 0.8 mm阈值可能有助于指导薄层黑色素瘤患者的护理分层。
  • 非黑色素瘤相关死亡风险在各厚度间相似,提示厚度主要影响黑色素瘤特异性结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Most patients who present with primary cutaneous melanomas have thin tumors (≤1.0 mm in Breslow thickness, ie, pT1a and pT1b). Although their prognosis is generally considered to be excellent, there is limited precise information on the association of risk of death with specific Breslow measurements in thin lesions. OBJECTIVE: To assess the relative effect of a 0.8-mm Breslow thickness threshold with respect to the incidence of both melanoma-related and nonmelanoma-related death. DESIGN, SETTING, AND PARTICIPANTS: Registry data for all Australians diagnosed with thin invasive primary melanomas between 1982 and 2014 were analyzed. Data were extracted from all 8 Australian state and territory population-based cancer registries. Dates and causes of death were obtained from the Australian National Death Index. Adults diagnosed with a first invasive primary melanoma of 1.0 mm or smaller in thickness were included. EXPOSURE: First invasive primary melanoma between 1982 and 2014. MAIN OUTCOMES AND MEASURES: The primary outcomes were melanoma-related deaths and nonmelanoma-related deaths. Competing-risk regression analyses and cause-specific analyses were performed to investigate the relationships between Breslow thickness subcategory (<0.8 mm versus ≥0.8 mm by 0.1-mm increments) and the primary outcomes. RESULTS: Overall, a cohort of 144 447 participants was included. The median (range) age was 56 (18-101) years and 78 014 (54.0%) were men. Median (IQR) follow-up was 15.0 (9.5-23.3) years. Crude incidence rates of melanoma-related death 20 years after diagnosis were 6.3% (95% CI, 6.1%-6.5%) for the whole cohort, 6.0% (95% CI, 5.7%-6.2%) for tumors smaller than 0.8 mm, and 12.0% (95% CI, 11.4%-12.6%) for tumors 0.8 to 1.0 mm. The corresponding 20-year melanoma-specific survival rates were 91.9% (95% CI, 91.6%-92.1%), 94.2% (95% CI, 94.0%-94.4%), and 87.8% (95% CI, 87.3%-88.3%), respectively. On multivariable analysis, tumor thickness of 0.8 to 1.0 mm was significantly associated with both a greater absolute risk of melanoma-related death (subdistribution hazard ratio, 2.92; 95% CI, 2.74-3.12) and a greater rate of melanoma-related death (hazard ratio, 2.98; 95% CI, 2.79-3.18) than thinner tumors (<0.8 mm). Risk of death from nonmelanoma-related causes was not associated with Breslow thickness. CONCLUSIONS AND RELEVANCE: In this study, the risk of melanoma-related death increased significantly for patients with primary tumors of 0.8 to 1.0 mm in thickness. The risk of death from nonmelanoma-ralated causes was similar across Breslow thicknesses of 0.1 to 1.0 mm. This analysis suggests that a 0.8-mm threshold for guiding the care of patients with thin primary melanomas.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Lo SN, Williams GJ, Cust AE, et al. Risk of Death Due to Melanoma and Other Causes in Patients With Thin Cutaneous Melanomas. JAMA Dermatol. 2025. PMID: 39661373. doi:10.1001/jamadermatol.2024.4900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。